<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>14</Volume>
				<Issue>5</Issue>
				<PubDate PubStatus="epublish">
					<Year>2013</Year>
					<Month>05</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>The XRCC3 Thr241Met Polymorphism Influences Glioma Risk - A Meta-analysis</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>3169</FirstPage>
			<LastPage>3173</LastPage>
			<ELocationID EIdType="pii">27759</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Findings from previous published studies regarding the association of the XRCC3 Thr241Metpolymorphism with glioma susceptibility have often been conflicting. Therefore, a meta-analysis including allavailable publications was carried out to make a more precise estimation of the potential relationship. &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;:By searching the electronic databases of Pubmed and Embase (up to April 1st, 2013), a total of nine case-controlstudies with 3,752 cases and 4,849 controls could be identified for inclusion in the current meta-analysis. Oddsratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;:This meta-analysis showed the XRCC3 Thr241Met polymorphism to be significantly associated with decreasedglioma risk in the allelic model (Met allele vs. Thr allele: OR= 0.708, 95%CI= 0.631-0.795). Moreover, we alsoobserved a statistically significant association between the XRCC3 Thr241Met polymorphism and reducedglioma risk in analyses stratified by ethnicity (Asian) and source of controls (hospital based) in the allelic model.&lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: Current evidence suggests that the XRCC3 Thr241Met polymorphism may be a risk factor forglioma development, especially in Asians.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Glioma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Polymorphism</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Meta-analysis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">XRCC3</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Asian ethnicity</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_27759_b3bbb7260ea6f5f2236640d18e11c9f2.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
